Li J, Kong MW, Xie YY, Wang ZB, Xu L, He GX. Efficacy and prognostic impact of Pericarpium Trichosanthis injection combined with nicorandil for intractable angina pectoris in elderly patients: A retrospective study. World J Cardiol 2023; 15(12): 633-641 [PMID: 38173907 DOI: 10.4330/wjc.v15.i12.633]
Corresponding Author of This Article
Mo-Wei Kong, MD, Doctor, Department of Cardiology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang Distinct, Guiyang 550018, Guizhou Province, China. 1600181272@qq.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Dec 26, 2023; 15(12): 633-641 Published online Dec 26, 2023. doi: 10.4330/wjc.v15.i12.633
Efficacy and prognostic impact of Pericarpium Trichosanthis injection combined with nicorandil for intractable angina pectoris in elderly patients: A retrospective study
Jun Li, Mo-Wei Kong, Yu-Yu Xie, Ze-Bi Wang, Li Xu, Guo-Xiang He
Jun Li, Mo-Wei Kong, Ze-Bi Wang, Li Xu, Guo-Xiang He, Department of Cardiology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Yu-Yu Xie, Department of Dermatology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Author contributions: Kong MW and Xie YY confirmed the authenticity of all the raw data; Kong MW wrote the manuscript; Li J, Wang ZB, and Xu L reviewed and revised the manuscript; and all authors read and approved the final manuscript.
Institutional review board statement: The GIGH Research Ethics Committee (Guiyang, China) confirmed that the study complied with ethical requirements.
Informed consent statement: This study was conducted in compliance with the requirements of the Ethics Committee and informed consent was obtained from all participating patients. The privacy and confidentiality of the patients were strictly protected, and any identifying information was removed during the process of manuscript preparation to ensure patient anonymity. In the case of specific diagnostic images or other identifiable patient-related information, previous written consent was obtained and the current consent status has been maintained.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used in this study was collected from the databases of Guiqian International General Hospital and Chengdu Fifth People’s Hospital, both of which are publicly available. The dataset includes information on demographics, medical history, and disease outcomes. The data can be accessed from the official website of Chengdu Fifth People’s Hospital (www.cd5120.com). It is important to note that the dataset contains personal and private information of patients, therefore, any use or redistribution of the data beyond the scope of this study is strictly prohibited due to privacy concerns.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mo-Wei Kong, MD, Doctor, Department of Cardiology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang Distinct, Guiyang 550018, Guizhou Province, China. 1600181272@qq.com
Received: September 5, 2023 Peer-review started: September 5, 2023 First decision: October 9, 2023 Revised: October 15, 2023 Accepted: November 30, 2023 Article in press: November 30, 2023 Published online: December 26, 2023 Processing time: 110 Days and 21.7 Hours
Abstract
BACKGROUND
Coronary artery disease (CAD) is a leading cause of global cardiovascular mortality. Refractory angina pectoris, a manifestation of CAD, requires effective drug treatments. Pericarpium Trichosanthis injection, a traditional Chinese medicine, improves cardiovascular symptoms, while nicorandil alleviates spasms and angina. Both have potential in treating CAD.
AIM
To investigate the therapeutic effects of combining Pericarpium Trichosanthis injection and nicorandil in elderly patients suffering from refractory angina caused by coronary heart disease.
METHODS
A retrospective analysis was conducted on the data of 130 patients diagnosed with refractory coronary heart disease. Based on the different treatment regimens administered during hospitalization, the patients were divided into a control group (58 cases) and a study group (72 cases). The control group received conventional treatment, which included aspirin, statins, and nitrate vasodilators. In addition to the conventional medication, the study group received a combination treatment of Pericarpium Trichosanthis injection and nicorandil.
RESULTS
After treatment, the study group showed significantly higher left ventricular ejection fraction and cardiac output, and lower brain natriuretic peptide and C-reactive protein levels compared to the control group. The study group also exhibited improvements in angina, quality of life, exercise endurance, and lipid profiles. Multivariate logistic regression analysis revealed a relationship of lipid levels and heart function with the combined treatment. Some patients in the study group experienced headaches during treatment, but no significant adverse reactions were observed. Follow-up showed that the treatment was well-tolerated, with no drug-related adverse reactions detected.
CONCLUSION
Combination of Pericarpium Trichosanthis injection and nicorandil is more effective than conventional treatment in improving symptoms and heart function in elderly patients with refractory angina pectoris.
Core Tip: Combining Pericarpium Trichosanthis injection and nicorandil shows promise in improving symptoms and heart function in elderly patients with refractory angina caused by coronary disease, as demonstrated by a retrospective study. This combination resulted in significant improvements in left ventricular function, cardiac output, angina frequency, quality of life, exercise tolerance, and lipid profiles. The therapy was well-tolerated with minimal adverse reactions. These findings highlight the potential of this combined treatment as an effective therapeutic option for refractory angina in elderly patients.
